# US 2014/0154279 A1 · Peptides capable of modulating the function of tirc7

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154279 A1
- Document ID: US20140154279A1
- Status: Published application
- Kind: A1
- Application number: 13/338,771
- Filed: 2011-12-28
- Published: 2014-06-05
- Earliest claimed: 2005-05-17
- Assignees: CellAct Pharma GmbH
- Inventors: Nalân UTKU
- Web page: https://patentgrep.com/patent/US20140154279A1

## CPC

- C07K 14/001: {by chemical synthesis}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 9/00: Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are peptides capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs) derived from the third extracellular domain of T-cell immune response cDNA7 (TIRC7) costimulatory molecule are described. Compositions comprising such peptides and their use for the treatment of immune diseases are provided.

## Claims

### Claim 1

A peptide capable of inhibiting proliferation of peripheral blood mononuclear cells, comprising a fragment of the amino acid sequence from the third extracellular domain of T cell immune response cDNA 7 protein.

### Claim 2 (depends on 1)

The peptide of claim 1, which comprises a fragment of the amino acid sequence shown in SEQ ID NO: 1.

### Claim 3 (depends on 1)

The peptide of claim 1 comprising or consisting of an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 5, or a fragment thereof.

### Claim 4 (depends on 1)

The peptide of claim 1, wherein said peptide comprises at least one selected from the group consisting of D-isomer amino acids, L-isomer amino acids, and a combination thereof.

### Claim 5 (depends on 1)

The peptide of claim 1, further comprising a heterologous amino acid or amino acid sequence at at least one of its N- and C-terminus.

### Claim 6 (depends on 1)

The peptide of claim 1, wherein said heterologous amino acid sequence comprises a His-tag or DHFR.

### Claim 7 (depends on 1)

The peptide of claim 1, wherein said peptide comprises the amino acid sequence of SEQ ID NO: 6 or 7.

### Claim 8 (depends on 1)

A composition comprising at least one peptide of claim 1.

### Claim 9 (depends on 8)

The composition of claim 8 which is a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9 further comprising an immunosuppressive.
